AUSTEDO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Austedo, and when can generic versions of Austedo launch?
Austedo is a drug marketed by Teva Branded Pharm and Teva and is included in two NDAs. There are fourteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and nineteen patent family members in thirty-three countries.
The generic ingredient in AUSTEDO is deutetrabenazine. One supplier is listed for this compound. Additional details are available on the deutetrabenazine profile page.
DrugPatentWatch® Generic Entry Outlook for Austedo
Austedo was eligible for patent challenges on April 3, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 18, 2034. This may change due to patent challenges or generic licensing.
There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
Summary for AUSTEDO
International Patents: | 119 |
US Patents: | 13 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 3 |
Clinical Trials: | 4 |
Patent Applications: | 18 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for AUSTEDO |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for AUSTEDO |
What excipients (inactive ingredients) are in AUSTEDO? | AUSTEDO excipients list |
DailyMed Link: | AUSTEDO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for AUSTEDO
Generic Entry Date for AUSTEDO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for AUSTEDO
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2/Phase 3 |
Vanderbilt University Medical Center | Phase 2/Phase 3 |
Fundacion Huntington Puerto Rico | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for AUSTEDO
Paragraph IV (Patent) Challenges for AUSTEDO
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
AUSTEDO | Tablets | deutetrabenazine | 6 mg, 9 mg and 12 mg | 208082 | 2 | 2021-04-05 |
US Patents and Regulatory Information for AUSTEDO
AUSTEDO is protected by thirteen US patents and four FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of AUSTEDO is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting AUSTEDO
Methods for the treatment of abnormal involuntary movement disorders
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Analogs of deutetrabenazine, their preparation and use
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Methods for the treatment of abnormal involuntary movement disorders
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting AUSTEDO
TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
Exclusivity Expiration: ⤷ Try a Trial
INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
Exclusivity Expiration: ⤷ Try a Trial
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Try a Trial
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-002 | Feb 17, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Teva Branded Pharm | AUSTEDO | deutetrabenazine | TABLET;ORAL | 208082-003 | Apr 3, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Teva Branded Pharm | AUSTEDO | deutetrabenazine | TABLET;ORAL | 208082-002 | Apr 3, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Teva Branded Pharm | AUSTEDO | deutetrabenazine | TABLET;ORAL | 208082-003 | Apr 3, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-001 | Feb 17, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Teva Branded Pharm | AUSTEDO | deutetrabenazine | TABLET;ORAL | 208082-003 | Apr 3, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for AUSTEDO
When does loss-of-exclusivity occur for AUSTEDO?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 13318182
Estimated Expiration: ⤷ Try a Trial
Patent: 18222896
Estimated Expiration: ⤷ Try a Trial
Patent: 20205297
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2015005894
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 83641
Estimated Expiration: ⤷ Try a Trial
Patent: 24804
Estimated Expiration: ⤷ Try a Trial
China
Patent: 4684555
Estimated Expiration: ⤷ Try a Trial
Patent: 1728971
Estimated Expiration: ⤷ Try a Trial
Patent: 6768882
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 97615
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 12232
Estimated Expiration: ⤷ Try a Trial
India
Patent: 62DEN2015
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 62601
Estimated Expiration: ⤷ Try a Trial
Patent: 12420
Estimated Expiration: ⤷ Try a Trial
Patent: 15528516
Estimated Expiration: ⤷ Try a Trial
Patent: 18162287
Estimated Expiration: ⤷ Try a Trial
Patent: 19059784
Estimated Expiration: ⤷ Try a Trial
Patent: 20189871
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 5372
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering AUSTEDO around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 114767672 | 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物 (Deuterated tetrabenazine or composition containing deuterated tetrabenazine) | ⤷ Try a Trial |
Poland | 3265085 | ⤷ Try a Trial | |
Japan | 2020189871 | 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態 (FORMULATION PHARMACOKINETICS OF DEUTERATED BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2) | ⤷ Try a Trial |
Japan | 2018162287 | 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態 (PHARMACOKINETICS OF DEUTERATED BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2) | ⤷ Try a Trial |
European Patent Office | 2610254 | DÉRIVÉS DEUTÉRÉS DE BENZOQUINOLINE EN TANT QU'INHIBITEURS DU TRANSPORTEUR DE MONOAMINE VÉSICULAIRE 2 (DEUTERATED BENZOQUINOLINE DERIVATIVES AS INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2) | ⤷ Try a Trial |
Norway | 3061760 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |